Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 477Neoplasms 292Breast Neoplasms 281Colorectal Neoplasms 223Neoplasm Metastasis 188Prostatic Neoplasms 168Ovarian Neoplasms 166Lung Neoplasms 155Multiple Myeloma 153Recurrence 132Melanoma 116Pancreatic Neoplasms 115Squamous Cell Carcinoma of Head and Neck 105Endometrial Neoplasms 99Stomach Neoplasms 98Leukemia, Myeloid, Acute 97Small Cell Lung Carcinoma 84Leukemia, Lymphocytic, Chronic, B-Cell 83Triple Negative Breast Neoplasms 81Lymphoma, Non-Hodgkin 81Carcinoma, Renal Cell 80Carcinoma, Hepatocellular 77Urinary Bladder Neoplasms 76Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 64Advanced Solid Tumors 64Lymphoma 60Glioblastoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 56Head and Neck Neoplasms 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Cancer × 90 days × Clear all
NCT07618260 2026-06-01

SIM0613-101

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Recruiting
294 enrolled

Advanced Solid Cancer

NCT07607678 2026-05-29

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

Boehringer Ingelheim

Phase 1 Recruiting
60 enrolled

Advanced Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡